The CGTLive™ Hematology specialty topic page houses the most up-to-date clinical news coverage in the field of hematology gene and cell therapy. It also includes video interviews with key opinion leaders in the field of hematology/oncology about the latest relevant FDA actions, clinical guideline updates, and clinical trial findings related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for various blood disorders.
August 29th 2025
Review top news and interview highlights from the week ending August 29, 2025.
Dr Bijal Shah Describes Brexucabtagene Autoleucel Toxicity in ZUMA-3
June 11th 2021The phase 2 ZUMA-3 trial of brexucabtagene autoleucel showed that it is possible to intervene early to prevent some toxicity, said Bijal Shah, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center.
EHA Preview: Advances, Outcomes in CAR T-Cell Therapies and Management Challenges
June 8th 2021With 5 chimeric antigen receptor (CAR) T-cell therapies approved by the FDA, and 299 agents in the pipeline, it’s no surprise that the virtual meeting of the European Hematology Association (EHA) will have a heavy presence of CAR T research being presented in sessions and posters.
Etranacogene Dezaparvovec Is Highly Unlikely the Cause of HCC in Hemophilia B Study
March 29th 2021Etranacogene dezaparvovec was "highly unlikely" to be the cause of hepatocellular carcinoma in a patient with hemophilia B enrolled in the phase 3 HOPE-B trial, according to an independent investigation.
FDA Approves Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
March 27th 2021The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.